PD-L1-targeting antisense oligonucleotide (OliPass)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NamePD-L1-targeting antisense oligonucleotide (OliPass)
Drug Alias NamePD-L1 Checkpoint Inhibitor (OliPass)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesOlipass Co
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOlipass Co
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A